ASLAN Pharmaceuticals will host –

MENLO PARK, Calif. and SINGAPORE, June 06, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (ASLN), an immunology-focused clinical-stage biopharmaceutical company developing innovative treatments to transform the lives of patients, announced today that it will host the third and final webinar in its series of Key Opinion Leader (KOL) events on the emerging atopic dermatitis (AD) landscape and eblasakimab (ASLAN004) on Wednesday, June 22, 2022 at 10:00 a.m. ET.

Dr. Peter A Lio, MD, Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University, will be the third KOL to speak at ASLAN’S A4 webinar series: Aspects of Atopic Dermatitis and ASLAN004. The webinar will include a presentation by Dr. Lio on the limitations of the current AD treatment landscape and the resulting unmet medical needs.

Dr. Lio will highlight patient journeys to illustrate the potential of new treatments in patients who do not optimally meet current standards of care and discuss comorbidities faced by patients with type 2 inflammation. Lio has published over 150 peer-reviewed publications on Alzheimer’s disease and serves as a director on the board of the National Eczema Association, the largest US nonprofit organization for patients with Alzheimer’s disease.

Dr. Carl Firth, CEO of ASLAN Pharmaceuticals, will share new insights from recent AD market research and provide insight into eblasakimab (ASLAN004) – a new first-in-class monoclonal antibody in phase 2b clinical development for the treatment of moderate to severe AD. Eblasakimab targets the IL-13 receptor α1 subunit (IL-13Rα1), one of the components of the type 2 receptor. By blocking the type 2 receptor, eblasakimab prevents interleukin 4 (IL-4) and interleukin 13 (IL-13) signaling – the main drivers of inflammation and itchiness in AD. The unique mechanism of action has the potential to provide a differentiated safety and efficacy profile, as well as an improved dosing regimen.

A fireside chat will follow Dr. Lio’s presentation which will focus on how new entrants can be positioned alongside existing therapies to meet the unmet needs of AD patients. A live question and answer session will follow the formal presentations.

How to register

To register for this webinar, please click here. A replay of the event will be available on ASLAN Pharmaceutical’s Investor Relations website.

About the featured KOL

Dr. Peter A Lio, MD, is a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine and director of the Northwestern University Eczema Care and Education Center.

Dr. Lio received his medical degree from Harvard Medical School, where he completed his training in dermatology and served as Chief Resident in Dermatology. Dr. Lio completed his pediatric residency at Boston Children’s Hospital. Dr. Lio was a full-time professor at Harvard for three years, serving at Beth Israel Deaconess Medical Center and Boston Children’s Hospital, before moving to Northwestern and Lurie Children’s Hospital.

Currently, Dr. Lio is a board member and scientific advisory committee member of the National Eczema Association, a member of the Atopic Dermatitis Expert Resource Group of the American Academy of Dermatology, and a founding faculty member of the program. of Integrative Dermatology, a training course for board-certified Dermatologists seeking to extend an integrative treatment approach into their practice outside of what is taught in conventional medical schools.

Dr. Lio has spoken nationally and internationally on atopic dermatitis and integrative medicine and remains active in clinical research. He is a Section Editor for the Archives of Diseases in Childhood and has published two textbooks and more than 150 publications in the peer-reviewed literature, receiving a Leader of Distinction Award, a Presidential Citation from the American Academy of Dermatology, and numerous teaching price.

About A from ASLAN4 (Atopic Dermatitis and ASLAN004 Aspects) Webinar Series

A of ASLAN4 Webinar Series: “Dialogues with International Opinion Leaders in Dermatology” is a series of key opinion leader (KOL) events on the emerging atopic dermatitis (AD) landscape and ASLAN004. The first episode of the series held in October 2021 featured Dr. Jonathan Silverberg MD, PhD, MPH, who discussed “the heterogeneity of atopic dermatitis,” and was followed by an episode featuring featured Dr. April Armstrong, MD MPH, who discussed “Key Factors Impacting Responses in Atopic Dermatitis Clinical Trials.” A replay of the first webinar can be accessed here and the replay of the second episode can be viewed here.

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLN, Financial) is an immunology-focused clinical-stage biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimaba potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral DHODH enzyme inhibitor in autoimmune diseases. ASLAN has a team in Menlo Park, California, and Singapore. For more information, visit or follow ASLAN on LinkedIn.

Media and IR contacts


Comments are closed.